CoChat
Sign Up
Cited by 28Blood Pressure and Hypertension StudiesGenetic Associations and EpidemiologyPharmacogenetics and Drug Metabolism

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide

Maitland-van der Zee, Anke-Hilse, Turner, Stephen T., Schwartz, Gary L., Chapman, Arlene B., Klungel, Olaf H., Boerwinkle, Eric·2005·Pharmacogenetics and Genomics
DOI 10.1097/01213011-200505000-00003
Open this paper in CoChat — free account

Abstract

OBJECTIVES: To assess the influence of variations in multiple candidate genes on inter-individual variation in diastolic blood pressure (DBP) response to hydrochlorothiazide. METHODS: A community-based sample of 585 adults with essential hypertension underwent monotherapy with hydrochlorothiazide for 4 weeks. In a nested case-control design, 195 individuals in the highest tertile of DBP response (responders) and 195 individuals in the lowest tertile of DBP response (non-responders) were genotyped for 45 polymorphisms in 19 candidate genes. For those polymorphisms where the set association approach found to be significantly associated with DBP response, logistic regression was performed to estimate the odds ratio (OR) for response associated variation in the identified genotype/haplotype. RESULTS: Two polymorphisms in the sodium channel gamma-subunit promotor gene, and a polymorphism in the endothelial nitric oxide synthase gene, were significantly associated with blood pressure response to hydrochlorothiazide. In the final experiment for the set association model P=0.038. In the logistic regression analyses, compared to subjects with the CT/CT haplotype of the SCNN1G gene, those with the GA/GA haplotype had OR 5.21 of being a DBP responder [95% CI 1.65-16.47]. Compared to subjects with the GT genotype of the ENOSA_rs1799983 polymorphism, those with the GG genotype had an OR 2.19 of being a DBP responder [95% CI 1.27-3.77]. CONCLUSIONS: Two polymorphisms in the sodium channel gamma-subunit promotor gene, and a polymorphism in the endothelial nitric oxide synthase gene, were associated with significant differences in odds of DBP response to hydrochlorothiazide. Follow-up studies are needed to define the functional genetic variations and their mechanisms of pharmacogenetic effects.

Overview

Integrity signals

Registry

Crossref · 10.1097/01213011-200505000-00003

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The rs1799983 polymorphism in NOS3 is reported to be associated with significant diastolic blood pressure response to hydrochlorothiazide.

    “The rs1799983 polymorphism in NOS3, is reported to be associated also with significant diastolic blood pressure response to hydrochlorothiazide [103]”

    From Fenofibrate and metabolic syndrome (2010) · cites this paper as [103]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 29

  1. Collins, 1994, Br Med Bull, 50, 272, 10.1093/oxfordjournals.bmb.a072892 · DOI
  2. Materson, 1993, N Engl J Med, 328, 914, 10.1056/NEJM199304013281303 · DOI
  3. Sander, 2000, Science, 287, 1977, 10.1126/science.287.5460.1977 · DOI
  4. Vesell, 1997, Ann Intern Med, 126, 653, 10.7326/0003-4819-126-8-199704150-00012 · DOI
  5. Nebert, 1999, Clin Genet, 56, 247, 10.1034/j.1399-0004.1999.560401.x · DOI
  6. Turner, 2001, Hypertension, 37, 739, 10.1161/01.HYP.37.2.739 · DOI
  7. Turner, 2003, Am J Hypertens, 16, 834, 10.1016/S0895-7061(03)01011-2 · DOI
  8. Schwartz, 2002, Kidney Int, 62, 1718, 10.1046/j.1523-1755.2002.00624.x · DOI
  9. Glorioso, 1999, Hypertension, 34, 649, 10.1161/01.HYP.34.4.649 · DOI
  10. Cusi, 1997, Lancet, 349, 1353, 10.1016/S0140-6736(97)01029-5 · DOI
  11. Sciarrone, 2003, Hypertension, 41, 398, 10.1161/01.HYP.0000057010.27011.2C · DOI
  12. Chapman, 2002, Kidney Int, 61, 1047, 10.1046/j.1523-1755.2002.00200.x · DOI
  13. Hoh, 2001, Genome Res, 11, 2115, 10.1101/gr.204001 · DOI
  14. Stephens, 2001, Am J Hum Genet, 68, 978, 10.1086/319501 · DOI
  15. Stephens, 2003, Am J Hum Genet, 73, 1162, 10.1086/379378 · DOI
  16. Iwai, 2001, Hypertension, 38, 86, 10.1161/01.HYP.38.1.86 · DOI
  17. Tsukada, 2002, J Hum Hypertens, 16, 789, 10.1038/sj.jhh.1001484 · DOI
  18. Lifton, 1992, Nat Genet, 2, 66, 10.1038/ng0992-66 · DOI
  19. Hansson, 1995, Nat Genet, 11, 76, 10.1038/ng0995-76 · DOI
  20. Kurland, 2002, J Hypertens, 20, 657, 10.1097/00004872-200204000-00023 · DOI
  21. Kurland, 2004, Am J Hypertens, 17, 8, 10.1016/j.amjhyper.2003.09.009 · DOI
  22. Psaty, 2002, JAMA, 287, 1680, 10.1001/jama.287.13.1680 · DOI
  23. del Monte, 1993, Circulation, 88, 854, 10.1161/01.CIR.88.3.854 · DOI
  24. Matsumura, 1999, Nat Genet, 21, 95, 10.1038/5036 · DOI
  25. Di Cerbo, 2002, J Clin Endocrinol Metab, 87, 898
  26. Neer, 1995, Cell, 80, 249, 10.1016/0092-8674(95)90407-7 · DOI
  27. Eckel, 1989, N Engl J Med, 320, 1060, 10.1056/NEJM198904203201607 · DOI
  28. Wilson, 2003, Proc Natl Acad Sci USA, 100, 680, 10.1073/pnas.242735399 · DOI
  29. Horisberger, 2004, Nephron Physiol, 96, 37, 10.1159/000076406 · DOI

Cited by

Sorted by citations

  • Fenofibrate and metabolic syndrome

    T. Kraja, A., A. Province, M., J. Straka, R., M. Ordovas, J., B. Borecki, I., & K. Arnett, D. (2010) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153010791213047 · Cited by 40

    “The rs1799983 polymorphism in NOS3, is reported to be associated also with significant diastolic blood pressure response to hydrochlorothiazide [103], has been proposed that it may increase the risk of developing diabetic nephropathy [104] and it has been found to be associated to central pulse pressure in the Framing…”

Metadata

Authors
Maitland-van der Zee, A.-H., Turner, S. T., Schwartz, G. L., Chapman, A. B., Klungel, O. H., & Boerwinkle, E.
Affiliations
  • Mayo Clinic (US)
  • Emory University (US)
  • Utrecht University (NL)
  • The University of Texas Health Science Center at Houston (US)
ORCID
Venue
Pharmacogenetics and Genomics
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2005-05
Volume
15
Issue
5
Pages
287-293
ISSN
1744-6872 (ISSN-L)
DOI
10.1097/01213011-200505000-00003
OpenAlex
W2008458855
Cited by
28
References
1
Citations by year
2023: 1 · 2020: 1 · 2016: 1 · 2015: 1 · 2014: 2 · 2012: 2
FWCI
3.20
Type
journal article
Language
en
Open access
closed
Locations
  • Pharmacogenetics and Genomics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Heart, Lung, and Blood Institute (R01 HL5330)
  • National Center for Research Resources (M01-RR00039, M01-RR00 585, M01RR000585, M01RR000039)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
hydrochlorothiazide, essential hypertension, candidate genes, SCNN1G, endothelial nitric oxide synthase, single nucleotide polymorphisms, haplotypes, thiazide diuretics, drug response variability
MeSH terms
Antihypertensive Agents, Blood Pressure, Female, Humans, Hydrochlorothiazide, Male, Middle Aged, Polymorphism, Genetic, Sodium Channels, Nitric Oxide Synthase, Cytochrome P-450 CYP11B2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review